Home › High Blood Pressure › NCT07174622
Longitudinal Real-world Clinical Outcomes Study on Symplicity Renal Denervation
Real-world Clinical Outcomes in Medicare Patients With Hypertension Treated With Symplicity Renal Denervation Plus Standard of Care Versus Standard of Care in Integrated EHR and Claims Data
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Enrolled in a Medicare plan * Diagnosis of uncontrolled hypertension * On a stable regimen of antihypertensive therapy Exclusion Criteria: * A prior RDN procedure * Diagnosis of secondary hypertension * Any condition for which RDN is contraindicated
About the study
This observational study will assess the long-term effectiveness of the RDN procedure for lowering blood pressure in Medicare patients with uncontrolled hypertension. This research will be conducted using de-identified electronic health records (EHR) and administrative health insurance claims data. Patients are enrolled through the submission of claims or encounter data to CMS.
What is being tested
- Renal Denervation (Symplicity Spyral™) (device)
Sponsor: Medtronic Vascular · Participants: 1,000 · Started: Oct 28, 2025
Contact the study team
- Kael Wherry, PhD, MS · Phone: 612-229-0714
Official record on ClinicalTrials.gov — NCT07174622
Locations in the U.S.
| Massachusetts | Beth Israel Deaconess Medical Center, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.